People: Nabi Biopharmaceuticals (NABI.O)

NABI.O on Consolidated Issue listed on NASDAQ Global Market

4.93USD
9 Feb 2010
Price Change (% chg)

$0.04 (+0.82%)
Prev Close
$4.93
Open
--
Day's High
$4.99
Day's Low
$4.75
Volume
257,198
Avg. Vol
254,223
52-wk High
$5.60
52-wk Low
$2.15

view people for:

Summary

Name Age Since Current Position
Cox, Geoffrey 65 2007 Non-Executive Chairman of the Board
Fahim, Raafat 55 2008 President, Chief Executive Officer, Acting Chief Financial Officer, Director
Kessler, Paul 54 2007 Senior Vice President - Clinical, Medical and Regulatory, Chief Medical Officer
Castaldi, David 69 1994 Director
Harvey, Richard 59 1992 Director
Jenckes, Linda 61 1997 Director
Sudovar, Stephen 62 2002 Director
Davis, Peter 62 2006 Director
Aryeh, Jason 40 2006 Director
Lynch, Timothy 39 2006 Director
» Insider Trading

Biographies

Name Description
Cox, Geoffrey Dr. Geoffrey F. Cox, Ph.D. has been a Director of Nabi Biopharmaceuticals since 2000 and has served as Non-Executive Chairman of the Board of Directors of the Company since February 2007. He has been Chairman, President and Chief Executive Officer of GTC Biotherapeutics, Inc., a biopharmaceutical company, since 2001. From 1997 to 2001, he was Chairman of the Board and Chief Executive Officer of Aronex Pharmaceuticals, Inc., a biotechnology company. From 1984 to 1997, he was employed by Genzyme Corporation, a biotechnology company, last serving as its Executive Vice President, Operations. Dr. Cox also serves on the board of directors of GTC Biotherapeutics, Inc. and on the board of directors of the Biotechnology Industry Organization and the Massachusetts Biotechnology Council.
Fahim, Raafat Dr. Raafat Fahim, Ph.D. serves as President, Chief Executive Officer and a Director of Nabi Biopharmaceuticals ince January 2008 and acting Chief Financial Officer of the Company since May 2008. From July 2007 to January 2008, Dr. Fahim served as Senior Vice President, Research, Technical and Production Operations of the Company and Chief Operating Officer and General Manager of the Biologics Strategic Business Unit. From March 2003 to July 2007, Dr. Fahim served as Senior Vice President, Research, Technical and Production Operations of the Company. From 2002 to 2003, Dr. Fahim was an independent consultant, working with Aventis Pasteur and other companies worldwide on projects that included manufacturing, process improvement, quality operations and regulatory issues. From 2001 to 2002, he served as President and Chief Operating Officer of Lorus Therapeutics, Inc., a biopharmaceutical company. From 1987 to 2001, Dr. Fahim was employed by Aventis Pasteur where he was instrumental in developing several vaccines from early research to marketed products. During his employment with Aventis Pasteur, Dr. Fahim held the positions of Vice President, Industrial Operations, Vice President, Development, Quality Operations and Manufacturing, Director of Product Development, and head of bacterial vaccines research/research scientist.
Kessler, Paul Dr. Paul Kessler, M.D., has been the Senior Vice President, Clinical, Medical and Regulatory and Chief Medical Officer of Nabi Biopharmaceuticals since March 2007. He joined Nabi Biopharmaceuticals in March 2005 as Senior Director, Clinical Research, and in April 2006, he was promoted to Vice President, Clinical Research. From 1998 to 2005, he served in several positions at GenVec, Inc., a gene therapy company, including Program Director, Director Clinical Research, Senior Director Clinical Research, and Executive Director Clinical Research. From 1989 to 1998, he was an Assistant Professor and later Associate Professor of Medicine at the Johns Hopkins University School of Medicine, where he conducted gene and cell therapy research and where he was an attending cardiologist on the Heart Failure and Transplant Service. He earned a B.S. from the University of Pittsburgh, a M.Sc. from the University of London, and an M.D. from Columbia University College of Physicians and Surgeons. He trained in Medicine and Cardiology at The Mount Sinai Hospital, New York, and Johns Hopkins.
Castaldi, David Mr. David L. Castaldi has been a Director of Nabi Biopharmaceuticals since 1994. Since 1994 he has been an independent consultant to the life science industry. Mr. Castaldi founded Cadent Medical Corp., a medical device company that was sold to Cardiac Science, Inc. While at Cadent, Mr. Castaldi served as Chairman of the Board from 1996 to 2001 and as Chief Executive Officer from 1998 to 1999. Previously, Mr. Castaldi was founder and Chief Executive Officer of BioSurface Technology, Inc., a Nasdaq-listed biotechnology company sold to Genzyme Corporation, and President of the worldwide protein-based pharmaceuticals division of Baxter International. He is a graduate of the University of Notre Dame and Harvard Business School. Mr. Castaldi serves on the boards of directors of four privately-held biopharmaceutical and medical device companies.
Harvey, Richard Mr. Richard A. Harvey, Jr. has been a Director of Nabi Biopharmaceuticals since 1992. He has been President of Stonebridge Associates, LLC, an investment banking firm, since 1996.
Jenckes, Linda Ms. Linda Jenckes has been a Director of Nabi Biopharmaceuticals since 1997. She has been President of Linda Jenckes & Associates, a government relations consulting firm that she founded, since 1995. Prior to that time she was Senior Vice President of the Health Insurance Association of America and also served as Principal Deputy Assistant Secretary for Legislation at the U.S. Department of Health and Human Services. Ms. Jenckes also serves on the boards of directors of the National Multiple Sclerosis Society and the National Polycystic Kidney Disease Research Foundation.
Sudovar, Stephen Mr. Stephen G. Sudovar has been a Director of Nabi Biopharmaceuticals since 2002. He currently serves as President and Chief Executive Officer of SGS Associates, a management consulting firm. From 1999 to 2005, Mr. Sudovar served as President and Chief Executive Officer of EluSys Therapeutics, Inc., a biotechnology company. From 1988 to August 1999, he was employed by Roche Laboratories, a division of F. Hoffmann-La Roche Ltd, a global healthcare company, last serving as its President. Mr. Sudovar also serves on the board of directors of Aastrom Biosciences, Inc.
Davis, Peter Mr. Peter B. Davis has been a Director of Nabi Biopharmaceuticals since 2006. He is currently an independent consultant. He served as Vice President Finance and Chief Financial Officer of XOMA Ltd., a biotechnology company, from 1994 to his retirement in June 2005. From 1991 to 1994 he served as Vice President Financial Operations for the Ares Serono Group, a global pharmaceutical company. From 1988 to 1991, he was Vice President, Chief Financial Officer of Akzo America Inc., a subsidiary of a diversified Dutch chemical company. From 1985 to 1988, he was Controller-International Division of Stauffer Chemical Corporation, and from 1972 to 1985, he was employed by PepsiCo Inc., last serving as Division Finance Director of Pepsi-Cola International.
Aryeh, Jason Mr. Jason M. Aryeh has been a Director of Nabi Biopharmaceuticals since 2006. He is the founder and general partner of JALAA Equities, LP, a private hedge fund formed in 1996 with a focus on biotechnology and specialty pharmaceutical companies. Mr. Aryeh also serves on the board of directors of Ligand Pharmaceuticals.
Lynch, Timothy Mr. Timothy P. Lynch has been a Director of Nabi Biopharmaceuticals since 2006. He has been Managing Member of Stonepine Capital LP, a life science focused investment fund since July 2008. From October 2005 to June 2008, Mr. Lynch was President and Chief Executive Officer of NeuroStat Pharmaceuticals, Inc., a start-up specialty pharmaceuticals company. From June 2005 to September 2005, Mr. Lynch was President and Chief Executive Officer of Vivo Therapeutics, Inc., a venture-backed specialty pharmaceuticals start-up. From October 2002 to June 2005, Mr. Lynch served as Chief Financial Officer of Tercica, Inc., a biopharmaceutical company. From 1999 to June 2002, Mr. Lynch served as Chief Financial Officer of InterMune, Inc., a biopharmaceutical company. He was involved with the initial public offerings of both biopharmaceutical companies. Previously, Mr. Lynch served as Director of Strategic Planning and as a pharmaceutical sales representative at Elan Corporation, PLC, a pharmaceutical company. He started his career at Goldman, Sachs & Co. and Chase Securities, Inc. Mr. Lynch is a Director of Allos Therapeutics, BioForm Medical, Inc. and Insite Vision. Mr. Lynch received his B.A. in Economics from Colgate University and his M.B.A. from the Harvard Graduate School of Business.

Basic Compensation

Name Fiscal Year Total
Cox, Geoffrey --
Fahim, Raafat 1,547,190
Kessler, Paul 660,264
Castaldi, David --
Harvey, Richard --
Jenckes, Linda --
Sudovar, Stephen --
Davis, Peter --
Aryeh, Jason --
Lynch, Timothy --
As Of 26 Dec 2008

Options Compensation

Name Options Value
Cox, Geoffrey 0 0
Fahim, Raafat 251,259 0
Kessler, Paul 0 0
Castaldi, David 0 0
Harvey, Richard 0 0
Jenckes, Linda 0 0
Sudovar, Stephen 0 0
Davis, Peter 0 0
Aryeh, Jason 0 0
Lynch, Timothy 0 0

Insider Trading

Name Shares Traded Price
ARYEH JASON 13,800 $5.49
ARYEH JASON 86,200 $5.49
ARYEH JASON 46,157 $5.29
ARYEH JASON 3,443 $5.29
ARYEH JASON 42,365 $5.24
ARYEH JASON 8,035 $5.24
ARYEH JASON 4,045 $5.24
DAVIS PETER B 2,200 $4.98
KESSLER PAUL D 602 $5.00
DAVIS PETER B 800 $4.98
KESSLER PAUL D 1,000 $4.92
KESSLER PAUL D 7,136 $4.90
KESSLER PAUL D 2,000 $4.91
KESSLER PAUL D 5,502 $4.89
KESSLER PAUL D 2,500 $4.90
ARYEH JASON 10,335 $5.01
ARYEH JASON 500 $4.89
ARYEH JASON 500 $5.22
ARYEH JASON 200 $5.25
ARYEH JASON 1,909 $5.04
ARYEH JASON 4,804 $4.74
ARYEH JASON 43,163 $4.99
ARYEH JASON 5,000 $4.75
ARYEH JASON 5,000 $5.10
ARYEH JASON 2,100 $5.02
» Full list on Insider Trading
view people for: